Xencor Inc logo

XNCR

Xencor Inc

$30.04

Earnings Summary

Revenue
$30.18Mn
Net Profits
$-33.98Mn
Net Profit Margins
-112.59%
PE Ratio
19.34

Highlights

Revenue:

Xencor Inc’s revenue fell -55.26% since last year same period to $30.18Mn in the Q2 2022. On a quarterly growth basis, Xencor Inc has generated -64.71% fall in its revenue since last 3-months.

Net Profits:

Xencor Inc’s net profit fell -165.03% since last year same period to $-33.98Mn in the Q2 2022. On a quarterly growth basis, Xencor Inc has generated -244% fall in its net profits since last 3-months.

Net Profit Margins:

Xencor Inc’s net profit margin fell -245.35% since last year same period to -112.59% in the Q2 2022. On a quarterly growth basis, Xencor Inc has generated -507.99% fall in its net profit margins since last 3-months.

PE Ratio:

Xencor Inc’s price-to-earnings ratio after this Q2 2022 earnings stands at 19.34.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Xencor Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.44
EPS Estimate Current Year
-0.44

Highlights

EPS Estimate Current Quarter:

Xencor Inc’s earning per share (EPS) estimates for the current quarter stand at -0.44 - a 26.67% jump from last quarter’s estimates.

EPS Estimate Current Year:

Xencor Inc’s earning per share (EPS) estimates for the current year stand at -0.44.

Key Ratios

Key ratios of the Xencor Inc post its Q2 2022 earnings

Return on Assets (ROA)
0.04
Return on Equity (ROE)
0.13
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Xencor Inc’s return on assets (ROA) stands at 0.04.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Xencor Inc’s return on equity (ROE) stands at 0.13.

Dividend Per Share (DPS):

Xencor Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.6
0.39
165%

Company Information

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

Organisation
Xencor Inc
Headquarters
Monrovia, California, United States
Employees
202
Industry
Health Technology
CEO
Bassil Dahiyat